#1 Clinical Trials Search in Europe

Bdc-1001

BDC-1001 is an innovative drug currently being studied in clinical trials for patients with HER2-positive cancers, particularly metastatic breast cancer and other solid tumors. This immune-stimulating antibody conjugate (ISAC) is designed to target HER2-expressing tumors and activate the body’s immune system to fight cancer. The ongoing trials aim to evaluate its effectiveness both as a single agent and in combination with other cancer treatments.

Table of Contents

What is BDC-1001?

BDC-1001 is a new type of cancer treatment currently being studied in clinical trials. It belongs to a class of drugs called immune-stimulating antibody conjugates (ISACs). This innovative medication is designed to target and treat cancers that express high levels of a protein called HER2 (human epidermal growth factor receptor 2)[1].

How Does BDC-1001 Work?

BDC-1001 works in a unique way to fight cancer:

  1. Targeting cancer cells: It contains a part that’s similar to a drug called trastuzumab, which specifically attaches to HER2 proteins on cancer cells.
  2. Activating the immune system: BDC-1001 also carries a substance that activates special receptors called TLR7/8. This helps to “wake up” the body’s immune system.
  3. Destroying cancer: By combining these two actions, BDC-1001 aims to help the body’s own immune system recognize and destroy HER2-positive cancer cells more effectively[1].

What Conditions Does BDC-1001 Treat?

BDC-1001 is being studied for the treatment of several types of HER2-positive cancers, including:

  • Metastatic breast cancer (cancer that has spread beyond the breast)
  • Colorectal cancer (cancer of the colon or rectum)
  • Gastroesophageal cancer (cancer of the stomach or esophagus)
  • Endometrial cancer (cancer of the uterus lining)
  • Other solid tumors that express HER2[2]

Current Clinical Trials

There are currently two main clinical trials studying BDC-1001:

  1. Phase 2 trial for metastatic breast cancer: This study is testing BDC-1001 alone and in combination with another drug called pertuzumab in patients with HER2-positive metastatic breast cancer who have previously been treated with a drug called trastuzumab deruxtecan (Enhertu®)[1].
  2. Phase 1/2 trial for various HER2-positive cancers: This study is looking at BDC-1001 alone and in combination with a drug called nivolumab (Opdivo®) in patients with different types of advanced HER2-positive cancers[2].

Potential Benefits

Researchers are studying BDC-1001 to see if it can provide benefits such as:

  • Shrinking tumors or slowing their growth
  • Improving survival rates
  • Offering a new treatment option for patients who have already tried other therapies
  • Potentially working better when combined with other cancer drugs[1][2]

Safety and Side Effects

As BDC-1001 is still in clinical trials, its full safety profile is not yet known. The ongoing studies are carefully monitoring patients for:

  • Side effects (called adverse events)
  • Serious side effects
  • Immune-related side effects
  • How well patients tolerate different doses of the drug[1][2]

It’s important to note that all potential side effects will be thoroughly evaluated before the drug can be approved for general use.

Combination Therapy

BDC-1001 is being studied both as a single agent and in combination with other cancer drugs:

  • With pertuzumab: Pertuzumab (also known as Perjeta®) is another drug that targets HER2. It works by preventing HER2 from partnering with other proteins, which can slow down cancer growth[1].
  • With nivolumab: Nivolumab (also known as Opdivo®) is a type of immunotherapy that helps the body’s immune system attack cancer cells[2].

These combinations are being tested to see if they can improve the effectiveness of treatment compared to using BDC-1001 alone.

Aspect Details
Drug Name BDC-1001
Drug Type Immune-stimulating antibody conjugate (ISAC)
Target HER2-expressing tumors
Administration Intravenous, every 2 weeks
Cancer Types HER2-positive metastatic breast cancer, other HER2-positive solid tumors
Trial Phases Phase 1/2 and Phase 2
Combination Therapies Tested with pertuzumab and nivolumab
Primary Outcomes Safety, tolerability, anti-tumor activity
Secondary Outcomes Duration of response, disease control rate, progression-free survival, overall survival

FAQ

  • What is BDC-1001? BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to target HER2-expressing tumors. It consists of a modified version of the antibody trastuzumab linked to a substance that activates the immune system.
  • What types of cancer is BDC-1001 being tested for? BDC-1001 is being tested primarily for HER2-positive metastatic breast cancer, as well as other HER2-positive solid tumors such as colorectal, gastroesophageal, and endometrial cancers.
  • How is BDC-1001 administered? BDC-1001 is administered intravenously (through a vein) every 2 weeks in the clinical trials.
  • Is BDC-1001 being tested alone or with other drugs? BDC-1001 is being tested both as a single agent and in combination with other drugs, such as pertuzumab and nivolumab, depending on the specific trial.
  • What are the main goals of the BDC-1001 clinical trials? The main goals are to evaluate the safety, effectiveness, and proper dosing of BDC-1001. Researchers are looking at how well it shrinks tumors, how long the effects last, and what side effects may occur.

Ongoing Clinical Trials on Bdc-1001

  • Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of BDC-1001 and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • HER2: Human Epidermal Growth Factor Receptor 2, a protein that promotes the growth of cancer cells. Some cancers, especially certain breast cancers, have higher levels of HER2 and are called HER2-positive.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Immune-stimulating antibody conjugate (ISAC): A type of drug that combines an antibody (which targets specific cancer cells) with a substance that activates the immune system to fight cancer.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in cancer treatment and diagnosis.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate (DCR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease.

References